Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALIST
2018-002162-38Phase 4Completed
- Sponsor
- CHRU Nancy
- Start
- Jul 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dulaglutide in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by CHRU Nancy. Primary endpoint: Histologic response at 52 weeks. Started Jul 2018; status: completed.
02
Drugs
dulaglutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2018-002162-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002162-38.